Latest Stories

Don’t miss our hot and upcoming stories
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?

Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting…

ByByAnuja Singh Sep 13, 2025
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?

Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long…

ByByAnuja Singh Sep 13, 2025
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences Future?

Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion…

ByByAnuja Singh Sep 13, 2025
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?

Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind,…

ByByAnuja Singh Sep 12, 2025
Scroll to Top